Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

Tolebrutinib did not show superiority over Aubagio (teriflunomide) in reducing relapse rates or MRI-detected inflammatory ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in ...

Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

"Without that [Agency for Healthcare Research and Quality] support, we will become ineffective." -- former U.S. Preventive ...

Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple sclerosis No drugs are currently approved to treat this type of MS WEDNESDAY, April 9, 2025 (HealthDay ...